Buscar
Kairos Pharma Ltd
KAPAAñadir a la lista de seguimiento
0.301USD
+0.001+0.37%
Cierre 07-31 16:00（ET）Cotizaciones retrasadas 15 min
6.44MCap. mercado
PérdidaP/E TTM
Más Datos de Kairos Pharma Ltd Compañía
Kairos Pharma, Ltd. is a clinical-stage biopharmaceutical company. It is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Its lead candidate, ENV105, is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. ENV105 focused on reversing drug resistance by targeting CD105 and restoring the effectiveness of standard therapies across multiple cancer types. ENV105 is in a Phase II clinical trial for castrate-resistant prostate cancer and a Phase I trial for lung cancer, with the trials aimed at addressing unmet medical needs. Its portfolio includes various drug therapies consisting of peptide and small molecule cancer immunotherapeutics KROS 101, 102, 201, 301, and 401 and therapeutic agents ENV 105 and 205.
Información de Kairos Pharma Ltd
Símbolo de cotizaciónKAPA
Nombre de la empresaKairos Pharma Ltd
Fecha de salida a bolsaSep 16, 2024
Director ejecutivoYu (John S)
Número de empleados1
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 16
Dirección2355 Westwood Blvd. #139
CiudadLOS ANGELES
Bolsa de valoresNASDAQ OMX – NASDAQ Basic Amex
PaísUnited States of America
Código postal90064
Teléfono18184045541
Sitio Webhttps://kairospharma.com
Símbolo de cotizaciónKAPA
Fecha de salida a bolsaSep 16, 2024
Director ejecutivoYu (John S)
Ejecutivos de Kairos Pharma Ltd
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.35M
-3.47%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
5.57K
-422.25%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
5.57K
-783.53%
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Hyun W. Bae, M.D.
Dr. Hyun W. Bae, M.D.
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. John S. Yu, M.D.
Dr. John S. Yu, M.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
5.35M
-3.47%
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Dr. Hansoo Michael Keyoung, M.D., Ph.D.
Independent Director
Independent Director
5.57K
-422.25%
Dr. Rahul Singhvi
Dr. Rahul Singhvi
Independent Director
Independent Director
5.57K
-783.53%
Dr. Neil Bhowmick, Ph.D.
Dr. Neil Bhowmick, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Dr. Ramachandran Murali, Ph.D.
Dr. Ramachandran Murali, Ph.D.
Vice President - Research and Development
Vice President - Research and Development
--
--
Mr. Douglas W. (Doug) Samuelson, CPA
Mr. Douglas W. (Doug) Samuelson, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Kairos Pharma Ltd?
Los cinco principales accionistas de Kairos Pharma Ltd son: Dr. John S. Yu, M.D.
¿Cuántas instituciones poseen acciones de Kairos Pharma Ltd (KAPA)?
A fecha de 2026Q1, 24 instituciones poseen acciones de Kairos Pharma Ltd, con un valor de mercado combinado de aproximadamente 1.15M, lo que representa el 5.38% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1122351.00.